Skip to main content
SpringerLink
Log in

Regulation of the Pharmaceutical Industry

And Now Pharmacoeconomic Research?

  • Leading Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Birch S, Gafni A. Cost-effectiveness/utility analyses: do current decision rules lead us to where we want to be? CHEPA Working Paper, pp. 91–96. McMaster University, Hamilton, Ontario, 1991

    Google Scholar 

  • Boyer JG, Hirsch JD, Osterhaus JT, Townsend RJ. Correspondence. Potential for bias in economic analyses. New England Journal of Medicine 325: 1385, 1991

    Article  Google Scholar 

  • Cairns J. Discounting and health benefits: another perspective. Health Economics 1: 76–79, 1992

    Article  PubMed  CAS  Google Scholar 

  • Coyle D, Tolley K. Discounting of health benefits in the pharmacoeconomic analysis of drug therapies: an issue for debate? PharmacoEconomics 2: 153–162, 1992

    Article  PubMed  CAS  Google Scholar 

  • Drummond MF. Cost-effectiveness guidelines for reimbursement of Pharmaceuticals: is economic evaluation ready for its enhanced status? Health Economics 1: 85–92, 1992

    Article  PubMed  CAS  Google Scholar 

  • Henry D. Economic analysis as an aid to subsidisation: the development of Australian guidelines for Pharmaceuticals. PharmacoEconomics 1: 54–67, 1992

    Article  PubMed  CAS  Google Scholar 

  • Hillman AL, Eisenberg JM, Pauly MV, Bloom BS, Glick H, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. New England Journal of Medicine 324: 1362–1365, 1991

    Article  PubMed  CAS  Google Scholar 

  • Ontario Ministry of Health. Guidelines for preparation of economic analysis to be included in submissions to Drug Programs for listing in the Ontario Drug Benefit Formulary/Comparative Drug Index, Ministry of Health, Toronto, 1991

    Google Scholar 

  • Parsonage M, Neuberger H. Discounting and health benefits. Health Economics 1: 71–76, 1992

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Glaxo Pharmaceuticals UK Limited, Stockley Park West, Uxbridge, Middlesex, UB11 1BT, England

    Nicholas E. J. Wells (Head of Pharmaceutical Economics)

Authors
  1. Nicholas E. J. Wells
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wells, N.E.J. Regulation of the Pharmaceutical Industry. PharmacoEconomics 2, 435–439 (1992). https://doi.org/10.2165/00019053-199202060-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199202060-00002

Keywords

Search

Navigation